(Q37235086)

19 August 2017

1 reference

title

Proton pump inhibitors: an update of their clinical use and pharmacokinetics (English)

1 reference

19 August 2017

Shaojun Shi

1

1 reference

PubMed ID

18679668

19 August 2017

Ulrich Klotz

series ordinal

2

1 reference

19 August 2017

5 August 2008

1 reference

European Journal of Clinical Pharmacology

19 August 2017

1 reference

19 August 2017

64

1 reference

19 August 2017

935-951

1 reference

19 August 2017

10

1 reference

https://scigraph.springernature.com/pub.10.1007/s00228-008-0538-y

19 August 2017

0 references

cites work

CYP2C19 polymorphism and proton pump inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS00228-008-0538-Y

Fexofenadine does not affect omeprazole pharmacokinetics: both are putative P-glycoprotein substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-008-0538-Y

Pharmacodynamic and kinetic effect of rabeprazole on serum gastrin level in relation to CYP2C19 polymorphism in Chinese Hans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-008-0538-Y

How can the current strategies for Helicobacter pylori eradication therapy be improved?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-008-0538-Y

Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-008-0538-Y

Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-008-0538-Y

Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban Asia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-008-0538-Y

The association of Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs in peptic ulcer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-008-0538-Y

Sequential Therapy versus Standard Triple-Drug Therapy for Helicobacter pylori Eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-008-0538-Y

Proton pump inhibitor treatment for acute peptic ulcer bleeding

21 January 2018

1 reference

12 December 2020

A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants

1 reference

12 December 2020

[Safety of proton pump inhibitors]

1 reference

12 December 2020

Therapeutic effects of 10 mg/day rabeprazole administration on reflux esophagitis was not influenced by the CYP2C19 polymorphism

1 reference

12 December 2020

Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease

1 reference

12 December 2020

Long-term lansoprazole control of gastric acid and pepsin secretion in ZE and non-ZE hypersecretors: a prospective 10-year study

1 reference

12 December 2020

Safety of potent gastric acid inhibition

1 reference

12 December 2020

Effects of single doses of rabeprazole 20 mg and esomeprazole 40 mg on 24-h intragastric pH in healthy subjects

1 reference

12 December 2020

Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment

1 reference

12 December 2020

Chronic proton pump inhibitor therapy and the risk of colorectal cancer

1 reference

12 December 2020

Lack of significant effect of grapefruit juice on the pharmacokinetics of lansoprazole and its metabolites in subjects with different CYP2C19 genotypes

1 reference

12 December 2020

Effect of pantoprazole versus other proton pump inhibitors on 24-hour intragastric pH and basal acid output in Zollinger-Ellison syndrome.

1 reference

12 December 2020

Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report

1 reference

12 December 2020

A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease

1 reference

12 December 2020

Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study

1 reference

12 December 2020

1 reference

12 December 2020

Medical management of gastroesophageal reflux disease

1 reference

12 December 2020

Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease

1 reference

12 December 2020

Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes

1 reference

12 December 2020

Clinical use and pharmacological properties of selective COX-2 inhibitors

1 reference

12 December 2020

Esomeprazole: prevention and treatment of NSAID-induced symptoms and ulcers

1 reference

12 December 2020

St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole

1 reference

12 December 2020

Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams

1 reference

12 December 2020

A meta-analysis: comparison of esomeprazole and other proton pump inhibitors in eradicating Helicobacter pylori

1 reference

12 December 2020

Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a mainten

1 reference

12 December 2020

Long-term use of proton pump inhibitors does not affect the frequency, growth, or histologic characteristics of colon adenomas

1 reference

12 December 2020

Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan

1 reference

12 December 2020

CYP2C19 genotype and the PPIs--focus on rabeprazole

1 reference

12 December 2020

Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians

1 reference

12 December 2020

The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis

1 reference

12 December 2020

Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes?

1 reference

12 December 2020

Review article: intragastric and oesophageal pH monitoring in patients with gastro-oesophageal reflux disease

1 reference

12 December 2020

4-day triple therapy with rabeprazole, amoxicillin and clarithromycin in the eradication of Helicobacter pylori in patients with peptic ulcer disease--A pilot study

1 reference

12 December 2020

Eradication of Helicobacter pylori Does Not Reduce the Incidence of Gastroduodenal Ulcers in Patients on Long-term NSAID Treatment: Double-Blind, Randomized, Placebo-Controlled Trial

1 reference

12 December 2020

Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers

1 reference

12 December 2020

The cost-effectiveness and budget impact of intravenous versus oral proton pump inhibitors in peptic ulcer hemorrhage

1 reference

12 December 2020

Lack of a pharmacokinetic interaction between lansoprazole or pantoprazole and theophylline

1 reference

12 December 2020

Maintenance oral pantoprazole therapy is effective for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion

1 reference

12 December 2020

Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases

1 reference

12 December 2020

Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors

1 reference

12 December 2020

Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole

1 reference

12 December 2020

[Role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users]

1 reference

12 December 2020

Proton pump inhibitors and the kidney: critical review

1 reference

12 December 2020

Long-term proton pump inhibitor use in children: a retrospective review of safety

1 reference

12 December 2020

Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status

1 reference

12 December 2020

The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study

1 reference

12 December 2020

Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes

1 reference

12 December 2020

Restorative impact of rabeprazole on gastric mucus and mucin production impairment during naproxen administration: its potential clinical significance

1 reference

12 December 2020

Acid-suppressive effects of rabeprazole: comparing 10mg and 20mg twice daily in Japanese Helicobacter pylori-negative and -positive CYP2C19 extensive metabolisers.

1 reference

12 December 2020

Gastro-oesophageal reflux disease

1 reference

12 December 2020

Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitis

1 reference

12 December 2020

Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas

1 reference

12 December 2020

Review article: pH, healing and symptom relief with rabeprazole treatment in acid-related disorders

1 reference

12 December 2020

On-demand therapy for gastroesophageal reflux disease

1 reference

12 December 2020

Pantoprazole 40 mg is as effective as esomeprazole 40 mg to relieve symptoms of gastroesophageal reflux disease after 4 weeks of treatment and superior regarding the prevention of symptomatic relapse

1 reference

12 December 2020

Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions.

1 reference

12 December 2020

Treatment of gastroesophageal reflux disease

1 reference

12 December 2020

Influence of fluconazole on the pharmacokinetics of omeprazole in healthy volunteers

1 reference

12 December 2020

Sequential regimens for Helicobacter pylori eradication.

1 reference

12 December 2020

Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial

1 reference

12 December 2020

Proton-pump inhibitor therapy in patients with gastro-oesophageal reflux disease: putative mechanisms of failure

1 reference

12 December 2020

CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori

1 reference

12 December 2020

Proton-pump inhibitors and outcome of endoscopic hemostasis in bleeding peptic ulcers: a series of meta-analyses.

1 reference

12 December 2020

1 reference

12 December 2020

Treatment with proton pump inhibitors in acute non-variceal upper gastrointestinal bleeding: a meta-analysis

1 reference

12 December 2020

The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics

1 reference

12 December 2020

NSAID-associated adverse effects and acid control aids to prevent them: a review of current treatment options

1 reference

12 December 2020

Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study

1 reference

12 December 2020

Review article: management of peptic ulcer bleeding-the roles of proton pump inhibitors and Helicobacter pylori eradication

1 reference

12 December 2020

Pantoprazole infusion as adjuvant therapy to endoscopic treatment in patients with peptic ulcer bleeding: prospective randomized controlled trial

1 reference

12 December 2020

Lack of Pharmacokinetic Interaction between Esomeprazole and the Nonsteroidal Anti-Inflammatory Drugs Naproxen and Rofecoxib in Healthy Subjects

1 reference

12 December 2020

Clinical significance of the cytochrome P450 2C19 genetic polymorphism

1 reference

12 December 2020

Effect of timing of dosing in relation to food intake on the pharmacokinetics of esomeprazole

1 reference

12 December 2020

Intra-oesophageal pH profiles and pharmacokinetics of pantoprazole and esomeprazole: a crossover study in patients with gastro-oesophageal reflux disease

1 reference

12 December 2020

Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.

1 reference

12 December 2020

A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole (40 mg) and omeprazole (20 mg) for the treatment of erosive esophagitis

1 reference

12 December 2020

Proton pump inhibitors and gastric neoplasia

1 reference

12 December 2020

Low-dose intravenous pantoprazole for optimal inhibition of gastric acid in Korean patients

1 reference

12 December 2020

Comparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer diseases.

1 reference

12 December 2020

Systematic review: Proton pump inhibitor-associated acute interstitial nephritis

1 reference

12 December 2020

Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture

1 reference

12 December 2020

Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial

1 reference

12 December 2020

Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study

1 reference

12 December 2020

A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects

1 reference

12 December 2020

An open-label study of rabeprazole in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion

1 reference

12 December 2020

Intravenous proton pump inhibitor therapy: a rationale for use.

1 reference

12 December 2020

Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial

1 reference

12 December 2020

Pharmacokinetics and tolerability of rabeprazole sodium in subjects aged 12 to 16 years with gastroesophageal reflux disease: an open-label, single- and multiple-dose study.

1 reference

12 December 2020

Suppression of gastric acid with intravenous esomeprazole and omeprazole: results of 3 studies in healthy subjects.

1 reference

12 December 2020

Summing the risk of NSAID therapy

1 reference

12 December 2020

CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor

1 reference

12 December 2020

[Omeprazole-induced acute cholestatic hepatitis]

1 reference

12 December 2020

Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study

1 reference

12 December 2020

Effect of Helicobacter pylori infection and NSAIDs on the risk of peptic ulcer bleeding

1 reference

12 December 2020

NSAIDs-induced gastrointestinal damage. Review

1 reference

12 December 2020

Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study

1 reference

12 December 2020

Perioperative acute upper gastrointestinal haemorrhage in older patients with hip fracture: incidence, risk factors and prevention

1 reference

12 December 2020

Effect of CYP2C19 polymorphism on the safety and efficacy of omeprazole in Japanese patients with recurrent reflux oesophagitis

1 reference

12 December 2020

Oral proton pump inhibitors are as effective as endoscopic treatment for bleeding peptic ulcer: a prospective, randomized, controlled trial

1 reference

12 December 2020

Review article: the clinical pharmacology of proton pump inhibitors

1 reference

12 December 2020

Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations

1 reference

12 December 2020

Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population

1 reference

12 December 2020

Bleeding peptic ulcer in the elderly: risk factors and prevention strategies

1 reference

12 December 2020

Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in health volunteers

1 reference

12 December 2020

Pharmacokinetic drug interaction profiles of proton pump inhibitors

1 reference

12 December 2020

Effect of esomeprazole and rabeprazole on intragastric pH in healthy Chinese: an open, randomized crossover trial

1 reference

12 December 2020

Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status

1 reference

12 December 2020

Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients

1 reference

12 December 2020

Can Helicobacter pylori eradication regimens be shortened in clinical practice? An open-label, randomized, pilot study of 4 and 7-day triple therapy with rabeprazole, high-dose levofloxacin, and tinidazole

1 reference

12 December 2020

Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders

1 reference

12 December 2020

CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms

1 reference

12 December 2020

Interaction studies of omeprazole with mefloquine, pyrimethamine and sulfadoxine

1 reference

12 December 2020

A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease

1 reference

12 December 2020

Cytochrome P450 2C19 polymorphism influences the preventive effect of lansoprazole on the recurrence of erosive reflux esophagitis

1 reference

12 December 2020

Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers.

1 reference

12 December 2020

Prevention and treatment of NSAID-induced gastroduodenal injury

1 reference

12 December 2020

Pharmacokinetic considerations in the eradication of Helicobacter pylori

1 reference

12 December 2020

The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism

1 reference

12 December 2020

Coadministration of lansoprazole and naproxen does not affect the pharmacokinetic profile of methotrexate in adult patients with rheumatoid arthritis

1 reference

12 December 2020

Seven-day therapy for Helicobacter pylori in the United States

1 reference

12 December 2020

Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers

1 reference

12 December 2020

Rabeprazole is superior to omeprazole for the inhibition of peptone meal‐stimulated gastric acid secretion in Helicobacter pylori‐negative subjects

1 reference

12 December 2020

[Side effects of proton pump inhibitors (PPIs)]

1 reference

12 December 2020

Comparative study of proton pump inhibitors for triple therapy in H. pylori eradication

1 reference

12 December 2020

The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus

1 reference

12 December 2020

10 day sequential therapy was more effective than 10 day triple drug therapy for eradicating Helicobacter pylori infection

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of lansoprazole in children 13 to 24 months old with gastroesophageal reflux disease

1 reference

12 December 2020

Meta-analysis: proton-pump inhibition in high-risk patients with acute peptic ulcer bleeding

1 reference

12 December 2020

Acid-suppressive efficacy of a reduced dosage of rabeprazole: comparison of 10 mg twice daily rabeprazole with 20 mg twice daily rabeprazole, 30 mg twice daily lansoprazole, and 20 mg twice daily omeprazole by 24-hr intragastric pH-metry

1 reference

12 December 2020

Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials

1 reference

12 December 2020

Effect of intravenous application of esomeprazole 40 mg versus pantoprazole 40 mg on 24-hour intragastric pH in healthy adults

1 reference

12 December 2020

Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype

1 reference

12 December 2020

Plasma concentration of rabeprazole after 8-week administration in gastroesophageal reflux disease patients and intragastric pH elevation.

1 reference

12 December 2020

Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes

1 reference

12 December 2020

Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole

1 reference

12 December 2020

Effect of concomitant dosing of famotidine with lansoprazole on gastric acid secretion in relation to CYP2C19 genotype status

1 reference

12 December 2020

Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data

1 reference

12 December 2020

Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms

1 reference

12 December 2020

Comparing rates of dyspepsia with Coxibs vs NSAID+PPI: a meta-analysis

1 reference

12 December 2020

Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study.

1 reference

12 December 2020

Update on Therapeutic Options for Helicobacter pylori-related Diseases.

1 reference

12 December 2020

Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes

1 reference

12 December 2020

Guidelines for the management of Helicobacter pylori infection in Japan: current status and future prospects

1 reference

12 December 2020

Pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in patients with GERD and nocturnal heartburn

1 reference

12 December 2020

Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein

1 reference

12 December 2020

Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem.

1 reference

12 December 2020

Pharmacokinetics of rabeprazole following single intravenous and oral administration to healthy subjects

1 reference

12 December 2020

Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding

1 reference

12 December 2020

Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily--a randomized, two-way crossover study

1 reference

12 December 2020

Pantoprazole on-demand effectively treats symptoms in patients with gastro-oesophageal reflux disease

1 reference

12 December 2020

Systematic review and meta-analysis: enhanced efficacy of proton-pump inhibitor therapy for peptic ulcer bleeding in Asia--a post hoc analysis from the Cochrane Collaboration

1 reference

12 December 2020

Celecoxib versus a non-selective NSAID plus proton-pump inhibitor: what are the considerations?

1 reference

12 December 2020

Efficacy of pantoprazole 20 mg daily compared with esomeprazole 20 mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double-blind comparative trial - the EMANCIPATE study

1 reference

12 December 2020

Treatment and dosing of Helicobacter pylori infection: when pharmacology meets clinic

1 reference

12 December 2020

Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States

1 reference

12 December 2020

Esomeprazole-based therapy in Helicobacter pylori eradication: a meta-analysis

1 reference

12 December 2020

Effects of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: a systematic review

1 reference

12 December 2020

Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers

1 reference

12 December 2020

Systematic review and meta-analysis: is 1-week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer?

1 reference

12 December 2020

Lansoprazole: pharmacokinetics, pharmacodynamics and clinical uses

1 reference

12 December 2020

Proton pump inhibitor treatment for acute peptic ulcer bleeding

1 reference

12 December 2020

Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies

1 reference

12 December 2020

Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study

1 reference

12 December 2020

Functional heartburn and non-erosive reflux disease

1 reference

12 December 2020

Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world

1 reference

12 December 2020

Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants

1 reference

12 December 2020

Acid-suppressive effects of various regimens of omeprazole in Helicobacter pylori-negative CYP2C19 homozygous extensive metabolizers: which regimen has the strongest effect?

1 reference

12 December 2020

The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis

1 reference

12 December 2020

Appropriate use of intravenous proton pump inhibitors in the management of bleeding peptic ulcer

1 reference

12 December 2020

Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of omeprazole in Chinese people

1 reference

12 December 2020

Role of intravenous omeprazole in patients with high-risk peptic ulcer bleeding after successful endoscopic epinephrine injection: a prospective randomized comparative trial

1 reference

12 December 2020

Systematic review: maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken 'on-demand'.

1 reference

12 December 2020

Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotype in healthy Chinese subjects

1 reference

12 December 2020

Proton pump inhibitor-induced acute interstitial nephritis

1 reference

12 December 2020

Long-term treatment of gastro-oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on-demand treatment compared with continuous treatment

1 reference

12 December 2020

Peptic ulcer disease today

1 reference

12 December 2020

[Management of gastroesophageal reflux disease (GERD) with refractory to standard dose of proton pump inhibitor]

1 reference

12 December 2020

Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding

1 reference

12 December 2020

Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations

1 reference

12 December 2020

American College of Gastroenterology guideline on the management of Helicobacter pylori infection

1 reference

12 December 2020

Combined analysis of three crossover clinical pharmacology studies of effects of rabeprazole and esomeprazole on 24-h intragastric pH in healthy volunteers

1 reference

12 December 2020

Proton pump inhibitor therapy for peptic ulcer bleeding: Cochrane collaboration meta-analysis of randomized controlled trials

1 reference

12 December 2020

[Influence of CYP2C19 polymorphism and Helicobacter pylori status on the antisecretory effect of omeprazole in gastroesophageal reflux disease].

1 reference

12 December 2020

Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: A randomized, open-label study

1 reference

12 December 2020

Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes

1 reference

12 December 2020

Review article: similarities and differences among delayed-release proton-pump inhibitor formulations

1 reference

12 December 2020

Pharmacokinetics of omeprazole in healthy adults and in children with gastroesophageal reflux disease

1 reference

12 December 2020

Pharmacogenomics of proton pump inhibitors

1 reference

12 December 2020

Pantoprazole based therapies in Helicobacter pylori eradication: a systematic review and meta-analysis

1 reference

12 December 2020

Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities

1 reference

12 December 2020

The choice of proton pump inhibitor: does it matter?

1 reference

12 December 2020

Increasing incidence of clostridium difficile-associated diarrhea in African-American and Hispanic patients: association with the use of proton pump inhibitor therapy.

1 reference

12 December 2020

Management of bleeding peptic ulcer: current status of intravenous proton pump inhibitors

1 reference

12 December 2020

Proton pump inhibitors and gastric neoplasia

1 reference

12 December 2020

Effect of omeprazole 10 mg on intragastric pH in three different CYP2C19 genotypes, compared with omeprazole 20 mg and lafutidine 20 mg, a new H2-receptor antagonist

1 reference

12 December 2020

Long-term proton pump inhibitor therapy and risk of hip fracture

1 reference

12 December 2020

Significant enhancement of gastric mucin content after rabeprazole administration: its potential clinical significance in acid-related disorders

1 reference

12 December 2020

Oral rabeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects

1 reference

12 December 2020

A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling

1 reference

12 December 2020

Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy

1 reference

12 December 2020

Comparison of the effects of single and repeated oral doses of lansoprazole and rabeprazole on ambulatory 24-hour intragastric pH in healthy volunteers

1 reference

12 December 2020

Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs

1 reference

12 December 2020

10.1007/S00228-008-0538-Y

Identifiers

DOI

1 reference

19 August 2017

1 reference

PubMed ID

18679668